List of Excipients in Branded Drug AMPHADASE

« Back to Dashboard

Amphadase Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 20, 2026

Amphadase is an FDA-approved ovine hyaluronidase injection marketed by Amphastar Pharmaceuticals. Its commercial value is tied less to excipient differentiation than to enzyme activity, sterile injectable manufacturing, supply reliability, and use in parenteral drug-delivery procedures. The product’s relatively simple excipient system creates opportunities for formulation suppliers, contract manufacturers, hospital channels, specialty distributors, and developers seeking a lower-cost alternative to recombinant human hyaluronidase.

What is Amphadase and how is it formulated?

Amphadase contains 150 USP units/mL of ovine hyaluronidase in a single-dose injectable presentation. Hyaluronidase temporarily hydrolyzes hyaluronic acid in the extracellular matrix, increasing tissue permeability and facilitating dispersion and absorption of co-administered subcutaneous or intramuscular fluids and drugs.[1]

Attribute	Amphadase profile
Active ingredient	Hyaluronidase, ovine
Strength	150 USP units/mL
Dosage form	Sterile injectable solution
Route	Subcutaneous, intramuscular, or use with appropriate infusion procedures
Sponsor	Amphastar Pharmaceuticals, Inc.
FDA application	NDA 021664
FDA approval	2004
Primary commercial use	Facilitation of subcutaneous fluid and drug administration
Prescription status	Prescription drug
Product category	Enzyme-based drug-delivery adjunct

The labeled formulation contains sodium chloride, phosphate-buffering salts, and water for injection. The inactive-ingredient system is designed to maintain tonicity, pH, and enzyme stability rather than provide a differentiated delivery profile.[1]

What excipients are used in Amphadase?

The Amphadase label identifies the following formulation components:

Component	Formulation role
Sodium chloride	Tonicity adjustment
Sodium phosphate monobasic monohydrate	Buffer system
Sodium phosphate dibasic heptahydrate	Buffer system
Water for injection	Vehicle

The product does not rely on a complex excipient platform such as a lipid carrier, polymeric depot, surfactant-rich system, or proprietary nanoparticle. This reduces formulation complexity but places greater importance on source-material control, protein stability, sterility assurance, container closure, and validated potency testing.

Why does the excipient strategy matter commercially?

Amphadase’s excipient strategy supports a low-complexity injectable product with a broad procedural use case. The principal commercial advantages are manufacturing simplicity and compatibility with co-administered solutions. The principal limitations are the narrow design space for reformulation and the need to protect enzyme activity during storage and administration.

A commercial reformulation must preserve:

• Hyaluronidase potency expressed in USP units.
• Solution clarity and sterility.
• Appropriate pH and osmolality.
• Compatibility with commonly administered fluids and drugs.
• Low risk of aggregation, precipitation, or loss of activity.
• Acceptable local tolerability after injection.

Excipient substitution is therefore more likely to produce incremental improvements than a new product category. Potential development goals include improved refrigerated stability, reduced adsorption to vial or syringe surfaces, lower particulate formation, longer in-use stability, and compatibility with prefilled or autoinjector systems.

Which excipient technologies could improve Amphadase?

Potential formulation strategies include:

1. Alternative phosphate buffering. Buffer optimization could improve pH control during refrigerated storage and reduce precipitation risk in combination-use settings.

2. Low-binding container systems. Protein adsorption to glass, elastomer, or polymer surfaces can reduce delivered potency. Siliconization levels, stopper composition, and syringe materials are relevant development variables.

3. Protein-stabilizing excipients. Sugars, polyols, amino acids, or carefully selected surfactants may improve stability, but each change would require assessment of enzyme activity, injection tolerability, and regulatory acceptability.

4. Prefilled syringe compatibility. A ready-to-use syringe could reduce preparation steps in emergency, hospital, home-infusion, or aesthetic settings.

5. Low-volume presentations. Smaller-volume formats could improve convenience where hyaluronidase is used to facilitate administration of a concentrated drug or biologic.

6. Combination packaging. Co-packaging Amphadase with compatible infusion products could create workflow value without changing the active formulation.

The strongest near-term commercial opportunities are likely to involve packaging, distribution, and procedural integration rather than a major excipient redesign.

What FDA regulatory status does Amphadase have?

Amphadase was approved by FDA under NDA 021664 as an ovine hyaluronidase injection.[1] It is regulated as a drug rather than as a biologic biosimilar. The product’s labeling covers use to increase tissue permeability and facilitate the absorption and dispersion of injected fluids and drugs.

The regulatory profile creates several practical consequences:

• A reformulation that changes inactive ingredients may require a supplement to the existing NDA.
• A new strength, route, delivery device, or combination use may require additional clinical, compatibility, or human-factors data.
• A competing ovine hyaluronidase product may pursue an abbreviated or 505(b)(2)-type strategy, depending on the reference product, formulation differences, and FDA requirements.
• A recombinant human hyaluronidase product is not automatically a biosimilar to Amphadase because the products differ in source, molecular characteristics, manufacturing process, and regulatory classification.

The product is distinct from Hylenex, which contains recombinant human hyaluronidase and is marketed by Halozyme Therapeutics. Source material and manufacturing technology are major differentiators between the two products.[2]

What is the Orange Book status of Amphadase?

Amphadase is associated with FDA NDA 021664 and is included in FDA product databases used to identify approved drug products.[3] The commercial significance of the listing is that the product has an approved NDA and can function as a regulatory reference for product and formulation comparisons.

The Orange Book analysis for Amphadase should distinguish three issues:

Issue	Amphadase implication
Approved product listing	Yes, under NDA 021664
Listed patents	No material patent barrier is identified in the cited public FDA product materials
Regulatory exclusivity	Original approval exclusivity has expired
Generic or follow-on pathway	Potentially available, subject to FDA determination and product-specific requirements
Biosimilar pathway	Not the natural pathway for an ovine enzyme drug

The absence of a significant listed-patent barrier shifts competitive protection toward manufacturing know-how, quality systems, supply contracts, formulation performance, and commercial execution.

When does Amphadase lose exclusivity?

Amphadase’s original regulatory exclusivity has expired. Its 2004 approval date places it well beyond the ordinary periods of new-drug exclusivity associated with an NDA.[1,3]

Protection category	Amphadase status
Five-year new chemical entity exclusivity	Expired or not applicable to the current commercial period
Three-year clinical-investigation exclusivity	Expired
Orphan-drug exclusivity	Not identified as the principal protection mechanism
Listed Orange Book patents	No material active patent barrier identified
Trade-secret protection	Potentially relevant to process, purification, analytics, and supply
Manufacturing barrier	More important than regulatory exclusivity

There is no meaningful single patent expiration date that defines Amphadase market entry risk. The product’s protection is primarily operational. Competitors would need to produce a sterile, potent, consistent hyaluronidase product and establish an FDA-acceptable regulatory pathway.

What patents protect Amphadase?

Public FDA product information does not identify a material active patent estate that would provide long-term Orange Book protection for Amphadase. The product’s original composition and use concepts are old relative to the product’s 2004 approval.

The potentially defensible intellectual-property areas are more likely to involve:

• Ovine tissue sourcing and raw-material controls.
• Extraction and purification processes.
• Viral and microbial clearance.
• Enzyme activity assays and reference standards.
• Stabilized liquid formulations.
• Container-closure systems.
• Prefilled syringe or device configurations.
• Combination packaging and administration workflows.
• Manufacturing scale-up and yield improvements.

These rights may be difficult to detect through the Orange Book because process patents, trade secrets, device patents, and non-listed formulation rights can sit outside the standard product-patent framework.

How strong is the Amphadase patent estate?

The patent estate is weak as a conventional product-exclusivity estate and stronger as a potential manufacturing and quality-control estate. The product is vulnerable to competition from a technically capable entrant that can reproduce the required enzyme activity, purity, sterility, and stability profile.

Patent category	Relative relevance
Broad composition claims	Low
Basic hyaluronidase use claims	Low
Ovine enzyme source claims	Moderate
Purification and process claims	Moderate
Stabilized injectable formulation claims	Moderate
Device and prefilled presentation claims	Moderate to high for a specific product
Trade secrets	Potentially high
Regulatory exclusivity	Low

Are there Paragraph IV challenges to Amphadase?

No material public Paragraph IV litigation involving Amphadase is identified in the cited FDA and public litigation materials. That does not eliminate future challenge risk. It indicates that the principal barrier to entry is not a widely litigated Orange Book patent estate.

A future abbreviated applicant could challenge listed patents if any are later listed or could pursue a regulatory pathway based on product similarity, clinical bridging, or a new application. The absence of a major listed-patent dispute makes early regulatory and manufacturing strategy more important than patent litigation strategy.

What generic entry risks exist for Amphadase?

The main generic-entry risks are technical and commercial:

1. Activity equivalence. Hyaluronidase potency must be demonstrated using appropriate biological or enzymatic assays.

2. Source-material comparability. Ovine-derived material introduces sourcing, animal-health, traceability, and consistency requirements.

3. Impurity control. Protein impurities, residual host materials, aggregates, and degradation products can affect safety and quality.

4. Sterile manufacturing. A competing product requires validated aseptic processing or sterilization controls suitable for a protein enzyme.

5. Formulation matching. Differences in pH, buffer, osmolality, or container interaction may trigger additional FDA questions.

6. Clinical bridging. The amount of clinical data will depend on the regulatory pathway and the extent of formulation or source differences.

7. Market access. Even with approval, a new entrant must obtain hospital, wholesaler, specialty-pharmacy, and procedural adoption.

The most credible launch scenario is a differentiated sterile injectable with comparable enzyme activity, competitive pricing, reliable supply, and a convenient presentation.

Which companies compete with Amphadase?

The main direct branded comparator is Hylenex, a recombinant human hyaluronidase product. Hylenex is produced using recombinant technology and has a different source and manufacturing profile.[2]

Product	Sponsor	Hyaluronidase source	Commercial positioning
Amphadase	Amphastar Pharmaceuticals	Ovine	Established injectable enzyme, price and supply-driven opportunity
Hylenex	Halozyme Therapeutics	Recombinant human	Human recombinant source, premium technology positioning
Compounded hyaluronidase	Compounding pharmacies	Variable	Local or specialty access, with quality and regulatory constraints

Amphadase can compete on cost, availability, and familiarity. Hylenex can compete on recombinant origin, supply-chain positioning, and integration with Halozyme’s broader drug-delivery technology portfolio.

What commercial opportunities exist for Amphadase?

Subcutaneous drug delivery

Hyaluronidase can improve dispersion and absorption of selected subcutaneous drugs and fluids. Growth in subcutaneous administration of biologics, immunoglobulins, oncology products, and specialty therapies creates demand for permeability-enhancing enzymes.

Commercial opportunities include:

• Co-development with injectable biologic sponsors.
• Supply agreements for specialty drug administration.
• Integration into home-infusion protocols.
• Use with concentrated subcutaneous fluids.
• Partnerships involving combination products.

The opportunity is strongest where subcutaneous delivery reduces infusion time, improves patient convenience, or enables a smaller administration setting.

Aesthetic medicine

Hyaluronidase is used clinically to manage certain complications associated with hyaluronic-acid dermal fillers. Demand is linked to injectable aesthetics, practitioner access, emergency inventory, and product trust.

Commercial growth can come from:

• Distribution through aesthetic medicine channels.
• Smaller emergency-use presentations.
• Practitioner education and stocking programs.
• Reliable supply contracts with clinics and physician networks.

This market is commercially attractive but sensitive to clinical labeling, medical-practice rules, and reputation risk.

Ophthalmic and procedural use

Hyaluronidase has procedural applications in ophthalmic and regional anesthesia settings. Sterile single-dose packaging and predictable potency are important in operating rooms and procedure centers.

Packaging and workflow improvements may create more value than excipient changes in these settings.

Hospital and home-infusion channels

Hospitals value products that have predictable availability, low preparation burden, and clear compatibility information. Home-infusion providers prioritize packaging, shelf life, shipping conditions, and ease of administration.

A prefilled syringe or co-packaged format could support higher realized pricing if it reduces waste, preparation time, or medication errors.

How does Amphadase compare with Hylenex?

Attribute	Amphadase	Hylenex
Enzyme source	Ovine	Recombinant human
Strength	150 USP units/mL	150 USP units/mL
Main differentiation	Established ovine injectable and potential cost advantage	Recombinant source and technology platform
Formulation complexity	Relatively simple	Product-specific recombinant formulation
Patent strategy	Limited conventional product protection	Stronger platform and delivery-technology context
Biosimilar exposure	Not applicable in the ordinary sense	Follow-on competition may be more complex
Commercial vulnerability	Price competition and supply substitution	Premium pricing and technology competition

The choice between products may depend on institutional policy, clinician preference, source-material concerns, price, availability, and intended use. For drug developers, Hylenex may be more attractive as a platform partner where recombinant human enzyme technology is required. Amphadase may be attractive where a conventional ovine product meets the use case at lower cost.

What manufacturing and IP barriers affect Amphadase?

Manufacturing is the principal barrier to entry. A commercially viable product requires:

• Controlled ovine source material.
• Consistent extraction or purification.
• Validated removal of adventitious agents.
• Reliable enzyme activity.
• Low aggregate and impurity levels.
• Aseptic fill-finish capability.
• Stability data for the final container.
• Lot-release methods tied to USP activity.

Trade secrets may protect process parameters more effectively than broad patents. These can include extraction conditions, purification sequencing, enzyme recovery, impurity clearance, and stability controls.

Geographic coverage also matters. Animal-derived products may face country-specific requirements involving source-country eligibility, transmissible spongiform encephalopathy controls, import documentation, and veterinary oversight. A global commercial strategy may therefore favor recombinant alternatives in some jurisdictions even when an ovine product is accepted in the United States.

What is the revenue exposure for Amphadase?

Amphastar does not generally disclose Amphadase revenue as a separate, fully transparent product line in its public financial reporting. Product-level revenue exposure is therefore best assessed through channel volume, pricing, market share, and supply continuity rather than a standalone reported figure.[4]

The commercial revenue drivers are:

• Hospital purchasing contracts.
• Specialty distribution.
• Aesthetic-practice demand.
• Home-infusion utilization.
• Subcutaneous biologic adoption.
• Competitor shortages or recalls.
• Product presentation and waste reduction.

The largest upside would come from securing recurring use in combination with high-volume subcutaneous therapies. The largest downside would come from low-cost entrants, recombinant-source preference, hospital formulary substitution, or manufacturing interruptions.

What settlement agreements and litigation affect Amphadase?

No significant public Amphadase patent settlement or Paragraph IV litigation is identified in the cited sources. The absence of a major settlement history means the competitive outlook is shaped by regulatory execution and manufacturing capability rather than by an established litigation timetable.

Any future dispute is more likely to concern:

• Manufacturing-process patents.
• Trade-secret misappropriation.
• Device or prefilled-syringe patents.
• Product quality or supply agreements.
• Trademark and distribution issues.
• Combination-product rights.

Key Takeaways

• Amphadase is a 150 USP units/mL ovine hyaluronidase injection marketed by Amphastar under NDA 021664.
• Its formulation uses a simple saline-phosphate vehicle and does not rely on a complex proprietary excipient platform.
• The best formulation opportunities involve stability, low-binding containers, prefilled syringes, and workflow integration.
• Original regulatory exclusivity has expired, and no material active Orange Book patent barrier is identified in the cited public materials.
• Manufacturing know-how, sterile processing, enzyme analytics, source-material control, and supply reliability are the main competitive barriers.
• Hylenex is the principal branded comparator and differentiates through recombinant human hyaluronidase.
• Commercial opportunities are concentrated in subcutaneous drug delivery, home infusion, hospital procedures, ophthalmic use, and aesthetic medicine.
• Amphadase revenue is not separately disclosed at a level that permits a reliable standalone revenue estimate.
• Generic or follow-on competition is technically feasible but requires substantial quality, potency, sterility, and regulatory execution.

FAQs

Is Amphadase a biologic or a conventional drug?

Amphadase is regulated as an approved drug product containing an enzyme. It is not ordinarily managed as a biosimilar reference product in the same way as a monoclonal antibody or other therapeutic protein approved under the Public Health Service Act.

Does Amphadase contain human-derived excipients?

The labeled formulation is based on sodium chloride, phosphate salts, and water for injection. The active enzyme is ovine-derived.

Can Amphadase be reformulated into a prefilled syringe?

Yes, a prefilled presentation is technically possible, but it would require container-closure, stability, extractables, leachables, dose-delivery, sterility, and human-factors evaluation.

Is recombinant hyaluronidase automatically interchangeable with Amphadase?

No. Recombinant human hyaluronidase and ovine hyaluronidase differ in source and manufacturing process. Interchangeability depends on the applicable FDA regulatory pathway and product-specific evidence.

What is the strongest commercial moat for Amphadase?

The strongest moat is the integrated manufacturing and quality system required to produce consistent sterile ovine hyaluronidase, not a broad publicly visible composition patent estate.

References

1. U.S. Food and Drug Administration. (2004). Amphadase (hyaluronidase injection, USP) prescribing information. Amphastar Pharmaceuticals, Inc.

2. U.S. Food and Drug Administration. (n.d.). Hylenex recombinant prescribing information. Halozyme Therapeutics, Inc.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. Amphastar Pharmaceuticals, Inc. (2024). Annual report on Form 10-K. U.S. Securities and Exchange Commission.